Drug intelligence / Profile preview

pembrolizumab + ibrutinib + rituximab

Development stage: Phase 2
Lead developer: Dana-Farber Cancer Institute
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination therapy consists of the PD-1 checkpoint inhibitor pembrolizumab, the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, and the anti-CD20 monoclonal antibody rituximab. It is being investigated in a Phase Ib/II clinical trial sponsored by the Dana-Farber Cancer Institute for the treatment of patients with relapsed or refractory primary central nervous system lymphoma (PCNSL). The regimen aims to leverage the synergistic effects of immune checkpoint blockade, targeted inhibition of B-cell receptor signaling, and antibody-dependent cellular cytotoxicity to overcome the blood-brain barrier and treat aggressive CNS lymphomas.

Other names: pembrolizumab + ibrutinib + rituximab combination therapy

Targets

BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on pembrolizumab + ibrutinib + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + ibrutinib + rituximab.